MedTrace Logo

Tumor-induced Osteomalacia Disease Monitoring Program

NCT04783428 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2026-01-21

No results posted yet for this study

Summary

The objectives of this observational study are to assess the long-term safety and long-term effectiveness of burosumab in patients with TIO who are being treated with burosumab as prescribed by their physician and to monitor the course of the underlying phosphaturic mesenchymal tumor (PMT) overtime in patients with TIO irrespective of their treatment status.

Conditions

  • Tumor-induced Osteomalacia (TIO)

Interventions

OTHER

No intervention

Access to any treatment is through authorized commercial use and not as part of this DMP

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Ultragenyx Pharmaceutical Inc

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2032-02-28
Completion
2032-02-28
FDA Drug
Yes

Countries

  • United States
  • Argentina

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04783428 on ClinicalTrials.gov